Live
FierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyEndpoints NewsARPA-H selects three teams in $100M effort to repair and regrow ailing jointsBioPharma DiveGilead continues M&A surge with $3.1B deal for ADC specialist TubulisEndpoints NewsTerns sold to Merck for 13% lower than pharma's initial offer because of clinical dataEndpoints NewsNovo launches high-dose Wegovy in the US; Evotec pressured to list its US unitBioWorldEmory University synthesizes new prostaglandin EP2 receptor antagonistsBioWorldChengdu Kanghong Pharmaceutical patents new lipoprotein(a)-lowering agentsBioWorldHoliday notice
BioPharma Dive Apr 7, 2026

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Original
Body unavailable. Use the original source.

Directory

59 All